Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City
Transactions News Contact Login
The FIRM Testimonials
Managing Partners Business Relationships
Investment Banking Services Proprietary Investment Opportunities
About The FIRM Testimonials Team Managing Partners Business Relationships Services Investment Banking Services Proprietary Investment Opportunities TransactionsNewsContactLogin
Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
Intuitive Venture PartnersDecember 10, 2020entera bio, 2020
Facebook0 Twitter LinkedIn0 Reddit Tumblr 0 Likes
Previous

9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock

Intuitive Venture PartnersDecember 10, 20209 Meters, 2020
Next

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Intuitive Venture PartnersNovember 9, 2020entera bio, 2020

Intuitive Venture Partners, LLC. • 777 Westchester Ave, Suite 101 • White Plains, NY 10604

Intuitive Venture Partners
777 Westchester Avenue,
White Plains, NY, 10604,
United States
212-612-3221 info@intuitivevp.com
Hours
Mon 8am - 5pm
Tue 8am - 5pm
Wed 8am - 5pm
Thu 8am - 5pm
Fri 8am - 5pm
 

2023 INTUITIVE VENTURE PARTNERS, LLC. ALL RIGHTS RESERVED. SECURITIES OFFERED THROUGH
NETWORK 1 FINANCIAL SECURITIES, INC., A REGISTERED BROKER-DEALER, MEMBER FINRA AND SIPC

broker-check-sml.png
Terms of UseContact